What is Can-C?
Can-C is a non-invasive, anti-oxidant eye drop - the only cataract eye drop proven in clinical trials to be effective in the treatment of cataracts and safe for long-term use. Approved and patented by Innovative Vision Products, who developed the technology behind this breakthrough in cataract treatment, Can-C contains N-acetylcarnosine a natural and powerful anti-oxidant.
While there are other commercially available N-acetylcarnosine eye-drops, some contain chemicals which should not be applied directly to the eye. Can-C is the only original, high purity, tested and approved brand that is safe for use in your eyes.
Can-C is also supported by eminent clinical and research dermatologist, Nicholas Perricone, MD, FACN, whose reputation for championing ground-breaking products is well-known.
How does Can-C work?
With age, our body produces more harmful free radicals and less natural antioxidants to defend against them. It’s this excessive free radical damage – known as oxidation – which can cause chronic tissue damage and lead to cataracts.
Extensive research has shown that a di-peptide (two amino acids linked together) known as carnosine holds the key to reversing free radical damage. Carnosine is found naturally in foods and in human cells. It acts as a protector, with both anti-oxidant and anti-glycation properties. As we get older our carnosine levels decrease, and there is a proven link between this decline and the onset of certain aging disorders, such as cataracts.
There are different forms of carnosine, but it is N-acetylcarnosine which has been shown to be highly effective in the treatment of cataracts. N-acetylcarnosine acts as a “carrier” of carnosine, delivering it directly into the aqueous humor of the eye (the fluid surrounding the lens). Administered in the form of eye drops, N-acetylcarnosine transforms into pure carnosine once inside the eye, making it a natural and powerful anti-oxidant.
What causes age-related eye problems?
As we get older, we become more susceptible to eye disorders such as cataracts, macular degeneration and glaucoma. The aging process leads to our body producing more harmful free radicals and less natural antioxidants to defend against them. And it’s this excessive free radical damage – or oxidation – which destroys proteins, enzymes and DNA, and can cause chronic tissue damage.
At the same time, our body is prone to a process known as glycation, which is when sugar and similar molecules attack our proteins and DNA, causing abnormal chemical bonds between molecules. When glycation and free radicals conspire, we are at greater risk of developing age-related chronic conditions such as cataracts and glaucoma.
What are cataracts?
Cataracts are a common age-related condition, which affect one in four people over the age of 65. They are caused by damage to the proteins inside the lens of the eye, due to glycation. The result is a hardening and clouding of the lens, which prevents light reaching the inside of the eye. It’s a bit like looking through frosted glass, blurring your vision and interfering with your sight. The damage is worsened by free radical action.
Although cataract surgery is one of the most commonly performed surgical operations in the world today – and generally accepted to be one of the safest – there is a significant complication rate. Some 30 to 50 per cent of patients who have cataracts removed require further lazer treatment within two years.
Is there an alternative to surgery?
N-acetylcarnosine is an important discovery because, for the first time ever, it offers an effective alternative to cataract extraction. N-acetylcarnosine taken on a regular basis has been shown to have a demonstrable affect on cataracts within one month of use. This is because N-acetylcarnosine not only protects the eye tissues from harmful free radicals, it also reverses existing damage.
Before the development of N-acetylcarnosine eye drops, the best that could be hoped for would be a slowing of the disorder. Now, at last, there is a viable alternative to surgery, avoiding further lazer treatment and allowing people to keep their natural lens rather than cope with an artificial one.
How effective is Can-C?
Statistics from trials show that Can-C eye-drops, applied for six months twice daily into the eye, in patients suffering from cataracts resulted in the following:
• 88.9 per cent showed improved glare sensitivity;
• 41.5 per cent had an improvement in the transmissivity of the lens;
• 90 per cent experienced improved visual acuity/sharpness of vision.
In the clinical trials, people who had senile cataracts for less than seven years experienced the fastest and greatest results. People who’d had cataracts for seven to 15 years still had good results, but as is usual with most treatments, the earlier Can-C is started, the better the results.
Is Can-C beneficial for anything else?
In addition to the proven results Can-C eye drops have demonstrated in treating cataracts, there are further potential benefits. Although the information is not yet published, Can-C is believed to have a positive effect on other eye disorders, such as:
• Open-angle primary glaucoma (in combination with beta-blockers)
• Corneal disorders
• Computer vision syndrome
• Eye strain
• Ocular inflammation
• Blurred vision
What is the dosage?
N-acetylcarnosine eye drops have been shown to have measurable affects within just one month of use. To achieve the best results, however, it is recommended you continue using them for a period of not less than three to five months. The sooner you start taking them after detecting a cataract, the better.
As a preventative measure, take two drops in both eyes once a day. As a treatment, two drops into the affected eye twice daily is the ideal regime. There is no benefit in exceeding this dose. You can continue to use N-acetylcarnosine eye drops occasionally even after treatment has been successful to prevent any re-occurrence.
Are there any side effects?
No serious side effects or contraindications have been reported in trials of N-acetylcarnosine. Stinging is a very rare side effect which some people may experience. Can-C is formulated to a Ph of 6.8, which is normal for the average person, but some individuals – either due to a medical condition or diet – may have a more acidic or alkaline balance in their body, which can cause stinging. Any stinging should naturally disappear with continued use, but if it is too uncomfortable Can-C use should be stopped.
If you are using other prescription eye drop medications, we recommend you seek guidance from your ophthalmic physician before using Can-C.
Although it is recognized as safe surgery, complications can occur, such as swelling, infection, retinal detachment, increased incidence of glaucoma (high internal eye pressure), and displacement of the new lens.
What causes Cataracts?
A cataract is a common, age-related condition affecting one in four people over the age of 65. It occurs when proteins inside the eye lens are damaged by a process called Glycation (where a protein molecule binds with a glucose molecule). This action forms opaque plaques in the eye lens, through which light cannot pass properly or sufficiently.
How does Can-C work?
N-acetylcarnosine is a natural chemical, similar to Carnosine, a combination of two amino acids (Alanine and Histidine). Carnosine has been studied comprehensively, and over 1000 scientific reports exist, documenting its antioxidant and anti-glycator action.
N-acetylcarnosine (NAC) works the same way as Carnosine, by inhibiting free radical damage and reducing the risk of Glycation. However, NAC is better utilized within the eye, because it remains biologically active for longer. It delivers L-Carnosine to the aqueous humor, (the fluid area surrounding the lens), where its anti-oxidant action protects the structural lens proteins against oxidation. It also reverses Glycation, so may be useful for addressing existing eye damage.
NAC eye drops have been tested in human, clinical trials on a number of senile cataract patients. When applied twice a day for a period of 6 months, statistics illustrated an 88.9% improvement in glare sensitivity; a 41.5% improvement in the ability of the lens to transmit light; and a 90% improvement in visual acuity.
Although as yet unpublished, Can-C is thought to be beneficial in treating a range of age-related eye conditions, including: presbyopia; open-angle primary glaucoma (in combination with beta-blockers); corneal disorders; computer vision syndrome; eye strain; ocular inflammation; blurred vision; dry eye syndrome; retinal diseases; vitreous opacities and lesions; complications of diabetes mellitus and other systemic diseases; contact lens difficulties, particularly with soft contact lenses.
N-acetylcarnosine eye-drops have shown quantifiable effects over a period of 1 month, however, better results can be achieved when used for a period of 3-5 months.